Laboratory of NF-κB Signaling, Institute of Molecular and Cell Biology (IMCB), 61 Biopolis Drive, Proteos, Singapore 138673, Singapore.
Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore 117596, Singapore.
Biosci Rep. 2020 Apr 30;40(4). doi: 10.1042/BSR20200256.
Allergen-specific immunotherapy (AIT) is currently the only potential treatment for allergies including allergic rhinitis (AR) and food allergies (FA) that can modify the underlying course of the diseases. Although AIT has been performed for over a century, the precise and detailed mechanism for AIT is still unclear. Previous clinical trials have reported that successful AIT induces the reinstatement of tolerance against the specific allergen. In this review, we aim to provide an updated summary of the knowledge on the underlying mechanisms of IgE-mediated AR and FA as well as the immunological changes observed after AIT and discuss on how better understanding of these can lead to possible identification of biomarkers and novel strategies for AIT.
变应原特异性免疫治疗（AIT）是目前唯一可能治疗过敏的方法，包括变应性鼻炎（AR）和食物过敏（FA），可以改变疾病的潜在进程。尽管 AIT 已经进行了一个多世纪，但 AIT 的精确和详细机制仍不清楚。以前的临床试验报告称，成功的 AIT 可诱导针对特定变应原的耐受性恢复。在这篇综述中，我们旨在提供 IgE 介导的 AR 和 FA 的潜在机制以及 AIT 后观察到的免疫学变化的最新知识总结，并讨论更好地了解这些机制如何有助于确定 AIT 的生物标志物和新策略。
